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Abstract
Following advancements in the field of genotoxicology, it has become widely accepted that 3D 
models are not only more physiologically relevant but also have the capacity to elucidate more 
complex biological processes that standard 2D monocultures are unable to. Whilst 3D liver models 
have been developed to evaluate the short-term genotoxicity of chemicals, the aim of this study 
was to develop a 3D model that could be used with the regulatory accepted in vitro micronucleus 
(MN) following low-dose, longer-term (5  days) exposure to engineered nanomaterials (ENMs). 
A comparison study was carried out between advanced models generated from two commonly 
used liver cell lines, namely HepaRG and HepG2, in spheroid format. While both spheroid systems 
displayed good liver functionality and viability over 14  days, the HepaRG spheroids lacked 
the capacity to actively proliferate and, therefore, were considered unsuitable for use with the 
MN assay. This study further demonstrated the efficacy of the in vitro 3D HepG2 model to be 
used for short-term (24  h) exposures to genotoxic chemicals, aflatoxin B1 (AFB1) and methyl-
methanesulfonate (MMS). The 3D HepG2 liver spheroids were shown to be more sensitive to DNA 
damage induced by AFB1 and MMS when compared to the HepG2 2D monoculture. This 3D model 
was further developed to allow for longer-term (5 day) ENM exposure. Four days after seeding, 
HepG2 spheroids were exposed to Zinc Oxide ENM (0–2 µg/ml) for 5 days and assessed using 
both the cytokinesis-block MN (CBMN) version of the MN assay and the mononuclear MN assay. 
Following a 5-day exposure, differences in MN frequency were observed between the CBMN and 
mononuclear MN assay, demonstrating that DNA damage induced within the first few cell cycles 
is distributed across the mononucleated cell population. Together, this study demonstrates the 
necessity to adapt the MN assay accordingly, to allow for the accurate assessment of genotoxicity 
following longer-term, low-dose ENM exposure.
Introduction
In recent years, 3D in vitro liver models have become increasingly 
useful tools for the genotoxic assessment of hazardous materials 
as they more accurately represent the physiological environment of 
the liver (1–5). It is widely accepted that the traditional in vitro 2D 
monocultures poorly represent the intricacies of the liver cells meta-
bolic activity in vivo and, therefore, are limited in their ability to 
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the expression of liver-specific enzymes and drug metabolism in pri-
mary human hepatocytes (albumin and cytochrome P450) were at 
much lower levels in 2D culture (8,9). Recent advances in tissue en-
gineering allow researchers to better simulate the liver environment 
using 3D cultures, providing a valuable tool for advancing the study 
of hepatotoxicity. At the International Workshop on Genotoxicity 
Testing (IWGT) it was recognised that 3D models, including those 
representing the liver, were deemed more physiologically relevant 
than the standard 2D monocultures (1).
Primary 2D human hepatocytes have been widely used in hep-
atotoxicity; however, they are not without limitations; for example, 
phenotypic variation between donors, rapid dedifferentiation and 
common loss of liver functionality (as indicated by reduced albumin 
and urea production) (7,10). The more physiologically relevant pri-
mary hepatocyte 3D liver model outperforms the standard 2D in vitro 
system, demonstrating long-term stability and the ability to maintain 
similar in vivo liver functionality (10). Primary hepatocyte 3D models 
have been reported to be efficacious in assessing longer-term toxicity 
using a variety of endpoints, such as cytotoxicity, cytokine produc-
tion and DNA damage induction, following repeated exposure to en-
gineered nanomaterials (ENMs) (11). Whilst 3D primary hepatocytes 
are relevant for longer-term toxicity testing, they are not suitable for 
use with the regulatory accepted micronucleus (MN) assay. The suc-
cess of this assay relies on cellular proliferation; however, many pri-
mary or differentiated 3D hepatic models are static (12).
Genotoxicity assessment involves the need for a battery of 
tests that are capable of quantifying the induction of point mu-
tation, structural chromosomal damage and numerical changes in 
chromosome number. The key in vitro assays utilised to evaluate 
these endpoints include the bacterial reverse mutation test, the 
MN assay and mammalian cell gene mutation tests (e.g. using the 
HPRT and xprt genes). Other DNA damage reporter assays that 
are used for screening purposes include the comet assay, gamma-
H2AX staining and, in more recent years, the use of ‘-omics’ 
technologies, that is, transcriptomics have been applied to screen 
for modifications and alternations in gene expression profiles fol-
lowing DNA damage induction. The MN assay is a reliable tech-
nique that measures fixed chromosomal damage demonstrated by 
the frequency of MN in cells that have undergone cell division, 
which results from aneugenic or clastogenic damage (13) and 
is, therefore, recommended as the ‘benchmark’ technique for as-
sessing DNA damage and genotoxicity in vitro (14,15). The MN 
assay has previously been adapted to accommodate advanced 3D 
tissue culture models for the assessment of hazardous materials. 
For example, Curren et  al. successfully modified the traditional 
MN assay for use with 3D EpiDerm Skin model, measuring 
genotoxicity using the reconstructed skin MN (RSMN) assay fol-
lowing chemical exposures for up to 72  h (16). Similarly, Wills 
et al. have also adapted the in vitro MN assay for genotoxic as-
sessment of the EpiDerm Skin model and TK6 cells following 24 h 
nanoparticle exposure (17). Shah et al. have recently developed a 
cost-effective, low-maintenance 3D HepG2 liver model that has 
been shown to maintain liver functionality and can be used for 
genotoxicity assessment using the cytokinesis-block MN assay 
(CBMN). The use and applicability of this 3D liver genotoxicity 
approach has been demonstrated with the chemicals benzo[a]
pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyri-
dine (PhIP), where interestingly, the 3D liver spheroid system was 
more sensitive to the induction of damage induced by these pro-
genotoxins than the comparative 2D HepG2 monocultures (3). 
The reason for this difference was the substantially higher expres-
sion levels of metabolic enzymes in the 3D liver spheroid models 
than in the 2D HepG2 cultured cells. Thus, the capability of the 3D 
models to more efficiently metabolise the BaP and PhIP exposures 
into their genotoxic metabolites resulted in greater genotoxicity 
being reported in the more complex culture system than when the 
standard CBMN assay was applied in 2D cell cultures.
The efficacy of the MN assay in 3D culture systems following 
exposure to ENMs must, however, also be considered, as it has long 
been recognised that the Organisation for Economic Co-operation 
and Development (OECD) test guidelines, which were primarily de-
veloped for chemicals, are not wholly appropriate for ENMs (13). 
For example, the CBMN assay requires the addition of cytochalasin 
B (Cyto B), a cytostatic agent that will halt cell division after one 
cell cycle and block cytokinesis, therefore resulting in the formation 
of clearly identifiable bi-nucleated cells (15). When exposing cells 
to chemicals, Cyto B can be added during or after the addition of 
the chemical. However, for ENM exposures, co-treatment of Cyto 
B with ENM has been shown to prevent cellular uptake of ENM; 
therefore, it is critical that Cyto B is added post-ENM exposure 
(13,18). More recently, a review of published data resulted in a series 
of recommendations on the genotoxic assessment of ENM (19). 
When evaluating the MN assay, of the 36 studies that satisfied the 
inclusion criteria, the conclusion was that there was a large degree 
of variation amongst assay approach and that standardisation of the 
MN assay to evaluate ENM is required (19). The MN assay is rou-
tinely used to evaluate genotoxicity associated with chemical com-
pounds. However, unlike chemical compounds which often can have 
short half-lives, many ENMs are biopersistent. They, therefore, do 
not always readily breakdown in biological systems and can result in 
a gradual intracellular accumulation with prolonged and/or repeated 
exposures (18).To further develop our understanding and accurately 
assess the impact of more realistic longer-term, low-dose ENM ex-
posure using the MN assay, it is necessary to have biological test 
systems and assays that facilitate this. The aim of this study, there-
fore, was to develop an advanced 3D liver spheroid model that could 
be used with the MN assay for genotoxicity assessment following 
longer-term exposure to test agents at low doses that are more repre-
sentative to an in vivo exposure system. This will be achieved via the 
modification of the protocol previously described in Shah et al. (3) to 
sustain extended culture periods of HepG2 and HepaRG liver spher-
oids in vitro while maintaining liver functionality and also adapt the 
approach to support the analysis of fixed DNA damage using the 
MN assay following longer-term ENM exposures.
Materials and Methods
Chemicals
Aflatoxin B1 (AFB1; Sigma Aldrich, UK), Cyto B and methyl-
methanesulfonate (MMS; Sigma Aldrich, UK) were prepared ac-
cording to manufacturer’s instructions. Stock solutions of AFB1 
(3  mM), MMS (1  mM) and Cyto B (1.5  mg/ml) were prepared 
in DMSO and stored at −20°C. ZnO ENM (JRC Nanomaterials 
Repository, Belgium) stock solutions (2.56  mg/ml) were prepared 
and dispersed as per the NanoGenoTox Dispersion Protocol (grant 
agreement no. 20092101, 2018) (20). Working stocks of both chem-
icals and ENMs were subsequently made fresh for each experiment.
Cell culture and maintenance
The human Caucasian hepatocellular carcinoma-derived epithelial 
cell line HepG2 (ECACC 85011430)  was cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) with 4.5  g/l D-glucose and 
L-glutamine (GIBCO, Paisley, UK) supplemented with 10% foetal 
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bovine serum and 1% penicillin/streptomycin (GIBCO, Paisley, UK). 
HepG2 cells were sub-cultured with trypsin/EDTA (0.05%) solution 
(GIBCO, Paisley, UK). HepG2 cells were sub-cultured every 3–5 days 
when 80% confluency was reached.
HepaRG cells (Biopredic International, HPR116) were thawed 
in HepaRGTM Thawing/Plating/General Purpose medium (Biopredic 
International, MIL600C with ADD670C), counted and seeded im-
mediately into spheroids using HepaRGTM Maintenance/Metabolism 
medium (Biopredic International, MIL600C with ADD620C). Both 
cell types were examined for morphology using a Zeiss Axiovert 25 
light microscope at ×40 objective.
3D spheroid liver models for acute exposures
HepG2 monolayers were used to form spheroids using the previ-
ously described hanging drop method (3). In short, HepG2 cells 
were trypsinised and a cell stock (2.0 × 105 cells/ml) was prepared. 
HepaRG cells were thawed straight from liquid nitrogen and via-
bility assessed using the trypan blue cell exclusion (TB) assay prior 
to preparing a cell stock of 2.0 × 105 cells/ml. A  total of cell sus-
pension (~4000 cells per 20 μl drop) was pipetted onto an inverted 
9.4-cm square petri dish lid (Greiner Bio-One, UK). Approximately 
100 drops were placed on each inverted petri dish lid. Subsequently, 
20 ml of phosphate buffered saline (PBS) was added to the base petri 
dish to prevent the drops from drying out during the culture period. 
The petri dish was placed into the incubator at 37°C and 5% CO2 
atmosphere. To maintain cell viability in the hanging drop, 6 μl of 
media was added to each drop on Day 3. Assessment of the spheroid 
morphology was examined using a Zeiss Axiovert 25 light micro-
scope at ×40 objective.
3D spheroid liver models for longer-term exposures
To support the growth of 3D spheroids over longer time periods, we 
have adapted the protocol previously described by Shah et  al. (3). 
Following trypsinisation of 2D HepG2 cells, a stock solution of cells 
was prepared. Next, 20 µl of the cell suspension (4000 HepG2 cells per 
20 μl hanging drop) was pipetted onto the inverted side of a 96-well 
tissue culture plate. To prevent the hanging drops from drying out, 
100 µl PBS was transferred into the wells of the 96-well plates. The lid 
of the 96-well plate was gently inverted and placed onto the 96-well 
plate. The plate was then placed in the incubator at 37°C with 5% 
CO2. Three days after seeding (into hanging drops), the PBS was re-
moved from each of the wells. The base of each well was coated with 
50 µl of 1.5% agarose gel (Figure 1). Once dried, 100 µl fresh media 
was added to the wells. The spheroids were then transferred into the 
wells by centrifugation at 200g for 3 min. The HepG2 spheroids, sus-
pended in the cell culture medium, were left to settle for 24 h, after 
which, they were ready to be exposed. To maintain cell viability over 
extended culture periods, the cell culture medium was refreshed every 
3 days, whereby 50 μl of media was aspirated and replaced with a 
fresh 50 μl of DMEM. Assessment of the spheroid morphology was 
examined using a Zeiss Axiovert 25 light microscope at ×40 objective.
Exposures
Short term
The spheroids were left in the hanging drop positions for 3  days 
(Figure 1). On Day 4, the hanging drops were treated with either 
AFB1 or MMS for 24 h, after which, Cyto B [6 μg/ml (Merck)] was 
added for an additional 24  h. The spheroids were harvested and 
Fig. 1. A schematic of the spheroid–ENM exposure timeline and MN assay specific adaptations.
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trypsinised as described below for the TB cytotoxicity assay. After 
the final centrifugation step, the pellet was re-suspended in 400 µl 
PBS. Slides were prepared for both cytokinesis-block proliferation 
index (CBPI) and semi-automated MN scoring as previously de-
scribed by Shah et al. and Chapman et al. (3,21).
Longer term
As detailed in the NanoGenoTox Dispersion Protocol (grant agree-
ment no. 20092101, 2018) (20), ZnO ENM was dispersed by son-
ication (Branson Sonifier 250, Ø 13  mm, 400 W output power, 
20 kHz) in 0.05% bovine serum albumin. Stock solution of ZnO 
was prepared at a concentration of 2.56 mg/ml, which was diluted 
in cell culture media to the required concentration (0.2–2  µg/ml). 
The protocol for exposing 3D liver spheroids to ENM was recently 
published by Llewellyn et al. (5). In brief, on Day 5, 50 µl of media 
was removed from the 96-well plate, taking caution not to disturb 
the spheroids, and replaced with 50 µl of ZnO ENM or AFB1. The 
plates were then incubated at 37°C for 5  days (Figure  1). AFB1 
(0.1 µM) was used as a positive chemical control. Three days fol-
lowing exposure, the media was replenished. Being careful not to 
disrupt the settled ENM and spheroids, 50 µl of media was aspirated 
from each well and replaced with 50 µl of fresh media. On Day 10, 
5 days post-ENM exposure, the spheroids were pooled and analysed 
for relative viable cell count (RVCC) using the TB assay and for 
genotoxicity using the mononuclear MN assay (as described below).
Cytotoxicity
Cell viability of the spheroids was assessed using the TB assay (GIBCO, 
Paisley, UK). Pooled spheroids were centrifuged at 230g for 5 min. To 
remove any residual media, the cell pellet was re-suspended in 1 ml PBS 
(GIBCO, Paisley, UK) and centrifuged at 230g for 5 min. To dissociate 
the spheroids, the cell pellet was re-suspended in trypsin/EDTA for 
8–10 min. Fresh media was added in equal volumes to neutralise the 
trypsin. The cells were centrifuged at 230g for 5 min and re-suspended 
in fresh media. Cell viability was then analysed using the standard TB 
assay (22). RVCC was calculated in accordance with the OECD guide-
lines and that previously described by (5,15).
Liver functionality assays
Spheroid albumin and urea levels were examined to assess HepG2 
and HepaRG spheroid liver-like functionality (BCG Albumin Assay 
Kit, MAK124 and Urea Assay Kit, MAK006, Sigma Aldrich, UK). 
All assays were performed as per manufacturer’s instructions. 
However, to ensure that samples fell within the standard curve, for 
the urea assay, the supernatants were diluted 1:10 with urea assay. 
On the day of harvest, spheroids were pooled and centrifuged at 
230g for 5 min. Cell culture supernatant was collected (1.5 ml) for 
use with the albumin and urea secretion assays. Samples were stored 
at -−80°C until the assays were performed.
MN assay
Manual slide preparation for CBPI
Manual slides were prepared to calculate the CBPI. Glass slides were 
cleaned with 70% ethanol and left to air dry. Slides were prepared 
using the previously described cytospin method (23). In short, 100 µl 
of cell suspension in PBS was added to the cytospin cassette. The 
cassettes were centrifuged at 500g for 5 min. Once dried, the slides 
were fixed with cold 90% methanol for 10 min. The slides were then 
left to dry overnight at room temperature and stained using 20% 
Giemsa stain diluted in phosphate buffer (pH 6.8). The CBPI was 
calculated using the Olympus BH2 microscope at ×100 objective on 
the first 500 cells according to the OECD guidelines(15).
Preparation of slides for scoring MN frequency using the 
automated Metafer System
The remaining cells in PBS are then fixed and placed on slides as 
previously described (23). The cell density on the slide was examined 
accordingly using the Olympus BH2 microscope at ×100 objective. 
Once the slides were dry, they were stored at −20°C until scoring. 
Prior to automated scoring using the Metafer system, 30  µl of 
Vectashield Mounting Medium with 4′,6-diamidino-2-phenylindole 
(DAPI) (Vector Laboratories, Peterborough, UK) was added in the 
dark and a coverslip applied. When scoring, detection of MN in 
binucleated (BN) or mononucleated cells were performed as pre-
viously described by Chapman et al. and Manshian et al. (21,23). 
A  minimum of 1000 BN cells or 2000 mononucleated cells were 
counted per exposure dose per replicate using the principles previ-
ously established by Fenech et al. (24) and in accordance with the 
OECD guidelines (15).
Statistical analysis
All experiments were performed three times independently (n = 3) 
with data presented as mean ± standard deviation (SD), unless 
stated otherwise. Statistical analysis was performed using Prism 8, 
GraphPad Software, Inc. Shapiro–Wilk test was used to calculate 
normality for each data set. For normally distributed data, either a 
one-way analysis of variance (ANOVA; HepG2 and HepaRG cell 
viability, HepG2 Cyto B; 2D and 3D HepG2 AFB1, MMS) or two-
way ANOVA (HepG2 vs. HepaRG; cell viability, albumin, urea; 2D 
vs. 3D HepG2 AFB1, MMS) with Bonferroni post hoc were used. 
Fisher’s Exact test was used to determine statistical significance of 
MN/BN% and MN/MN% when compared to the untreated con-
trol (P < 0.05). For non-parametric data, a Kruskal–Wallis test was 
used to calculate significance when there were more than two vari-
ables (MN/MN% vs. MN/BN%, RVCC vs. CBPI, ZnO ENM) or to 
 compare to the untreated control (RVCC and CBPI; P < 0.05).
Results
Characterisation of HepG2 and HepaRG 3D models 
for genotoxic assessment using the MN assay
HepG2 and HepaRG cells are commonly used in liver toxicology 
studies due to their capacity to retain many of the metabolic func-
tions of human liver cells. Urea and albumin production were as-
sessed using the supernatant from both models on Days 4, 7, 10 and 
14. As demonstrated in Figure 2A, there was a significant difference 
between the HepaRG and HepG2 cells (P < 0.001). Bonferroni’s post 
hoc test further revealed significant differences in the level of urea 
on Days 1 and 7 between the two cell types (P  < 0.033). HepG2 
spheroids demonstrated an overall reduced capacity to produce urea 
compared to HepaRG; however, this difference was less notable after 
10 days of culture. Additionally, no significant difference in albumin 
production was observed between the two cell types over the 14-day 
period (Figure 2B). Within the HepaRG model, a significant reduc-
tion in cell viability was observed on Days 10 and 14 when com-
pared to Day 1 (P < 0.05); no significant differences were observed 
for HepG2 spheroids over the 14 days when compared to Day 1 
(Figure  2C). When then two models were compared, there was a 
main effect for time (P  <  0.001); however, over that time period, 
post hoc analysis demonstrated no significant difference in viability 
between the two models (Figure 2C).
As currently described by the OECD test guideline 487 for the 
‘in vitro mammalian cell micronucleus assay’, it is necessary to en-
sure that, after cells have been exposed to a chemical, they must 
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undergo mitosis prior to being scored. The addition of Cyto B prior 
to nuclear division blocks the actin ring filaments, preventing the 
complete formation of two new daughter cells, resulting in the 
formation of a BN cell. Figure 3A and B demonstrates the opti-
misation of the incorporation of Cyto B into the CBMN assay in 
HepG2 3D spheroids. When evaluating the most appropriate Cyto 
B concentration to use, a small (1.997%) yet statistically signifi-
cant increase in the frequency of BN cells was recorded when ex-
posed to 9 µg/ml (P = 0.021) when compared to 6 µg/ml of Cyto 
B (Figure  3A). However, upon visual assessment following ex-
posure to 9 µg/ml, the spheroids displayed irregular morphology 
demonstrating loss of integrity of the outer layers and evidence 
of membrane blebbing that was not observed in cells treated with 
6 µg/ml (data not shown). Therefore, 6 µg/ml was selected for ex-
periments going forward. In addition to concentration, it is also 
important to consider the time of Cyto B application. As illustrated 
in Figure 3B, whilst no significant cytotoxicity was observed at any 
time point, a significantly higher BN cell frequency was apparent 
at 24  h post-treatment than that compared with any other time 
point (P < 0.01).
To determine the proliferative capacity of HepaRG spheroids, 
cells were exposed to increasing concentrations of Cyto B for 24 and 
30 h to capture a full cell cycle. No statistically significant differences 
were observed between the two time points or at any concentration 
of Cyto B for either genotoxicity or cytotoxicity (Figure  3C). 
However, what was apparent was the very low proliferative capacity 
of differentiated HepaRG 3D spheroids, which regardless of Cyto B 
concentration or exposure time, generated no more than a 9% BN 
cell frequency compared to 31% observed in HepG2 spheroids. This 
low induction of BN cells deems the HepaRG spheroid model un-
suitable for genotoxicity assessment using the MN assay. Therefore, 
HepG2 cell spheroids were selected for further development as a 
model for longer-term ENM exposures.
HepG2 3D liver model demonstrates increased 
sensitivity to pro-carcinogens compared to HepG2 
monolayers following acute exposures.
To investigate the sensitivity of 3D spheroids to a known genotoxic 
insult, both 2D and 3D HepG2 models were exposed to increasing 
concentrations of the well-known liver carcinogen AFB1 for 24 h 
and analysed using the CBMN assay. Figure 4A demonstrates a 
significant dose-dependent increase in MN frequency following 
exposure to AFB1 for both 2D (P < 0.001; 0.05–0.2 µM) and 3D 
(P < 0.05; 0.025–0.2 µM) HepG2 models when compared to the 
untreated control. When both 2D and 3D models were compared, 
the 3D model demonstrates a greater genotoxic effect. Bonferroni 
post hoc revealed a significant difference in MN frequency 
Fig. 2. Characterisation of HepG2 and HepaRG liver cells over 14 days in culture. (A) Urea and (B) albumin production and (C) viability of 3D HepG2 and HepaRG 
spheroids were evaluated over 14 days. Statistical differences between HepG2 and HepaRG spheroids were analysed using two-way ANOVA with Bonferroni 
post hoc (*P < 0.05). Data shown are expressed as mean ± SD, n = 3.
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detected between both 2D and 3D HepG2 cells at 0.025–0.2 µM 
(P < 0.001). At top dose (0.2 µM) in the 2D model, there is 3-fold 
(3.1) difference in MN when compared to the untreated control; 
on the other hand, in the 3D model, the MN frequency is nearly 
4-fold (3.7) higher than the untreated control. The CBPI demon-
strates no cytotoxicity as a result of AFB1 over the concentration 
range applied. This data demonstrates that 3D HepG2 spheroids 
are more sensitive to the DNA damage induced by AFB1 than the 
2D monoculture. It is suggested that this may be due to the in-
creased metabolic activity of 3D HepG2 models previously dem-
onstrated by Shah et al. (3) and, therefore, they are more efficient 
at converting AFB1 to the genotoxic metabolite than the same 
cells grown as 2D monocultures.
To investigate whether 3D HepG2 spheroids also demonstrated 
increased sensitivity to DNA damage induced by direct-acting 
genotoxins, both cell culture formats were exposed to increasing 
concentrations of the alkylating agent and direct-acting genotoxin 
MMS for 24 h (Figure 4B). Similarly, as demonstrated with AFB1, 
Figure 4B demonstrates a significant dose-dependent increase in MN 
frequency for both 2D (P < 0.05; 20–30 µM) and 3D (P < 0.001; 
(10–30 µM) HepG2 models when compared to the untreated con-
trol. No cytotoxicity was observed following MMS treatment. In 
contrast, Bonferroni post hoc testing revealed a significant difference 
in MN frequency when comparing the induction of DNA damage 
between the 2D and 3D model formats at 10 and 15µM (P < 0.05). 
Generally, however, there was little difference between the fold dif-
ference in the induction of genotoxicity over the control when com-
paring the 2D and 3D model formats, thus indicating that they had 
a very similar sensitivity to the induction of DNA damage by the 
direct-acting genotoxin MMS.
Modified hanging drop approach supports longer-
term viability of HepG2 spheroids
To maintain cell viability in the hanging drop during short-term ex-
posures, 6  μl of media was added to each 20  µl drop on Day 3; 
Fig. 3. Optimisation of Cyto B application for use with the CBMN assay. HepG2 3D liver spheroids were exposed to (A) 6 and 9 µg/ml Cyto B for 24 h and (B) 6 µg/
ml Cyto B for 12, 24, 36 and 48 h and analysed for percentage BN cell frequency. Statistical differences were analysed using (A) unpaired t-test (*P = 0.021) and 
(B) one-way ANOVA with Bonferroni post hoc (*P < 0.01). (C) HepaRG spheroids were exposed to increasing concentrations of Cyto B (3, 6 and 9 µg/ml) for 24 
and 30 h and analysed for percentage BN cell frequency and CBPI. Data shown are expressed as mean ± SD, n = 2.
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however, for longer-term exposures, continued addition of media to 
the droplet would result in the droplet becoming too large and, thus, 
would fall from the lid of the petri dish. In an effort to overcome 
this, spheroids were seeded onto the lid of a 96-well plate. After 
3 days, 100 µl of fresh media was added to the base of each well of 
the plate. The spheroids were then transferred into each of the wells 
containing fresh media by centrifugation. As seen in Figure 5A, after 
72 h, the HepG2 cells within the spheroid begin to elongate and form 
protrusions in an effort to reform a monolayer on the base of the 
96-well plate. To combat this issue and extend the longevity of the 
spheroid model, a layer of agarose (1.5% agarose in DMEM without 
phenol red) was added to the base of the 96-well plate (Figure 5C). 
Following the addition of the agarose layer, the spheroid forms a de-
fined round spheroid, with no protrusions (Figure 5B).
Table 1 below demonstrates the results of a comparison study 
of spheroid viability and urea and albumin production in both the 
presence and absence of an agarose layer added to the base of the 
96-well plate. No significant difference between urea and albumin 
production was observed between the two methods. Similarly, when 
comparing the viability at each time point, no significance was ob-
served; however, a significant difference is demonstrated in the total 
mean difference with cell viability in the presence and absence of 
agarose (P = 0.013; Figure 5D). To maintain the structural integrity 
of the spheroids and prolong viability of the culture over 10 days, it 
was concluded that the addition of a 1.5% agarose layer to the base 
of the 96-well plates prior to the addition of media was necessary to 
support longer-term exposures. This approach was implemented for 
the remainder of this study.
In vitro MN assay for longer-term ENM genotoxicity 
assessment
As demonstrated previously, the CBMN version of the MN assay 
with CBPI was performed, where, after a 24-h exposure, Cyto B was 
added for an additional 24 h, which results in the formation of BN 
cells. However, it was postulated that the damage encountered fol-
lowing longer-term exposure may occur at an earlier stage; therefore, 
the addition of Cyto B and counting MN in BN cells after a 5-day 
exposure could fail to accurately capture the true genotoxic insult. 
To investigate this, firstly using the CBMN approach, all MN in BN 
cells (MN/BN%) were scored with CBPI calculated as a measure 
of cytotoxicity (Figure  6A). A  non-dose-dependent induction of 
genotoxicity was observed, with the only significant difference noted 
between the untreated control and the lowest concentration 0.2 µg/
ml of ZnO (P = 0.037) and, as expected, with the positive control 
(0.1 µM AFB1, P < 0.001). Second, in the absence of Cyto B, cells 
were scored for MN in mononucleated cells (MN/MN %) and 
RVCC calculated as the measure of cytotoxicity (Figure 6B). A sig-
nificant increase in MN frequency was observed in all concentra-
tions of ZnO ENM compared to the untreated control (P < 0.007, 
0.025–30 µg/ml). Additionally, when compared, a significant differ-
ence (P  =  0.021) was observed between the two methods for as-
sessing MN frequency (MN/BN% and MN/MN%). No significant 
difference was observed between the two methods for cytotoxicity 
(CBPI and RVCC).
Discussion
The purpose of this study was to develop a 3D liver spheroid 
model that would support ENM genotoxicity assessment fol-
lowing exposure over a prolonged period (i.e. up to 5 days). Over 
the last decade, there have been a number of protocols published 
demonstrating the development of 3D liver models. However, a 
model that supports DNA damage testing using the MN assay fol-
lowing longer-term ENM exposure and associated genotoxic assess-
ment using the MN assay is yet to be established. Herein describes a 
method that supports the growth and maintenance of 3D liver spher-
oids over a total of 10, allowing for an extended exposure period of 
5 days.
In an effort to replace, reduce and refine the reliance on animal 
experimentation, substantial efforts have been placed on developing 
3D in vitro model systems that demonstrate greater physiological 
relevance and that mimic the liver-like functionality and metabolism 
seen in vivo. It is thought that the enhanced features of 3D models 
are due to the compact density of the spheroid, complex cell to cell 
interactions and signalling, making them an ideal candidate to im-
prove the state-of-the-art for genotoxicological testing (25). Using 
Fig. 4. Assessment of micronuclei frequency in 2D monocultures and 3D HepG2 spheroids following a genotoxic insult. 2D HepG2 monocultures and 3D 
spheroids were exposed to increasing concentrations of (A) Aflatoxin B1 (0–0.2 µM) and (B) MMS (0–30 µM) for 24 h and analysed for MN in BN cells (MN/BN%) 
and CBPI. Statistical significance was compared to the untreated control and was analysed by one-way ANOVA with Bonferroni post hoc (*P < 0.007). Data 
shown are expressed as mean ± SD, n = 3.









niversity user on 18 Septem
ber 2020
liver-specific functionality assays, our data demonstrates that 3D 
HepG2 spheroids maintain functionality for up to 14 days in culture 
as fully formed spheroids. HepaRG liver cells are widely used in drug 
development and toxicology, as they retain liver-like functionality. 
Using the same protocol, we generated a differentiated HepaRG 3D 
model and the two models showed comparable liver-like function-
ality. However, there was some variance between the two models in 
urea production, with the HepaRG model demonstrating the ability 
to maintain consistently high levels of urea over the 14 days, albeit 
only significant at Days 1 and 7. There was no significant differ-
ence in albumin levels over the 14 days between the two models; 
however, HepG2 levels appear to be lower. No differences in cell via-
bility were observed over the 14 days. Based on this metabolic data, 
it would appear that the HepaRG model exhibits a slight advantage 
over HepG2, which agrees with observations by others, although 
they are largely comparable (12).
An important feature of the MN assay is the requirement for 
cells to demonstrate a high proliferative capacity. This study dem-
onstrates a basal-level BN cell frequency following treatment with 
6 µg/ml Cyto B in 3D HepG2 cells, indicating that the cells within 
the spheroid (particularly at the periphery) are actively prolifer-
ating. Whilst this is lower than typically observed in 2D culture, 
Table 1. Characterisation of 3D liver spheroids in the presence and absence of agarose.
HepG2 cells No Agarose Agarose 
 Day 7 Day 10 Day 7 Day 10 





























Fig. 5. Modification of the hanging drop method to support longer-term ENM exposures. Spheroids were grown on the lid of a 96-well plate for 3 days; on Day 
4, they were transferred by centrifugation into the base of the plate containing media that was either (A) not coated in agarose or (B) coated in agarose. Images 
of the spheroids were obtained using light microscopy (×40 objective) after 72 h. Changes to spheroid structure are denoted by red arrows. Scale bar 20 µM. 
(C) Schematic of the modified hanging drop method with the addition of a 1.5% agarose layer that is used for the remainder of the study. (D) Viability of HepG2 
spheroids was calculated using the Trypan Blue assay in the presence and absence of agarose. Statistical significance was determined using an unpaired t-test 
(*P <0.01). Data shown are expressed as mean ± SD, n = 3.
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this level of proliferation is sufficient to support the MN assay. We 
found that 24 h was the optimal time point to capture cells that 
have been arrested after one cell cycle and presented as BN cells. 
In contrast to this, our data showed that HepaRG cells exhibit a 
very low proliferation rate. Despite adjusting the Cyto B concentra-
tion and exposure duration, the BN frequency for 24 h was 7.2%, 
whilst, for HepG2 spheroids, it reached 31.13%. The very low pro-
liferative capacity of differentiated HepaRG 3D spheroids deems 
them unsuitable for genotoxicity assessment using the MN assay. 
Interestingly, as demonstrated by others, this does not seem to be 
the case when HepaRG cells are cultured in 2D (26,27). However, 
for 3D spheroids, this data agrees with Mandon et al., who dem-
onstrated that HepaRG 3D spheroids had low levels of DNA topo-
isomerase II, a specific marker for cell division (2), confirming the 
quiescent nature of differentiated HepaRG spheroids. Therefore, if 
the endpoint for analysis is the MN assay, HepaRG in 3D spheroid 
format are not a practical cell model to be used. Jossé et al. previ-
ously described the adaptation of the HepaRG cell line to the MN 
assay for genotoxicity testing, which was facilitated by treating the 
HepaRG cells in 2D with epidermal growth factor to stimulate cell 
proliferation (27). To the best of our knowledge, this has not be 
explored in 3D HepaRG models but offers a potential strategy to 
overcome the quiescent nature of 3D HepaRG spheroids.
Shah et  al. have previously determined that HepG2 spheroids 
demonstrate increased efficacy over the standard 2D monoculture 
and can readily metabolise the pro-carcinogens B[a]-P and PhIP into 
their genotoxic metabolites, thus initiating an enhanced genotoxic 
response compared to 2D cultures (3). Similarly, our data confirms 
that 3D HepG2 spheroids detect greater levels of genotoxicity at low 
concentrations of the liver pro-carcinogen AFB1 compared to 2D 
monocultures. This may be due to the increase in metabolic func-
tion observed in 3D models (3,28,29). We also establish that the 
direct-acting genotoxin, MMS, induced similar levels of genotoxicity 
in both 2D and 3D models. The data demonstrates that the elevated 
number of MN observed in the 3D models with pro-carcinogens is 
not an artefact of the 3D system (e.g. DNA damage induced through 
enhanced metabolism). Although no significant cytotoxicity was 
observed between the two models, the CBPI was lower in the 3D 
spheroid model than the 2D monoculture following both AFB1 and 
MMS exposure. This coincides with that observed by Shah et al. who 
suggested that, due to the compact nature of the spheroid, it is pri-
marily the outer layer of cells that are rapidly dividing, whereas the 
cells within the spheroid core have a lower proliferation index (3).
In an effort to increase the longevity of the 3D culture, spheroids 
were seeded onto the lid of a 96-well plate as opposed to the lid of a 
square petri dish as previously described by Shah et al. (3). Following 
a 3-day incubation period to allow for spheroid formation, the spher-
oids were dropped by centrifugation into each well of the 96-well 
plate, which contained 100 µl media. However, during visual exam-
ination of the HepG2 spheroids, it was apparent that the naturally 
adherent nature of the HepG2 cells began affecting the structural 
integrity of the spheroid. The spheroids began to form protrusions 
in an effort to reform a monolayer on the base of each well. HepG2 
cells are, by nature, an adherent cell line and, when given the oppor-
tunity to attach to a surface, they will try to form a monolayer as 
demonstrated in the present study. To overcome this obstacle, 1.5% 
agarose was added to the base of each well prior to the addition 
of media. There was no significant difference in metabolic function 
(urea and albumin) in the 3D models in the presence of agarose. This 
agrees with numerous studies that demonstrate the use of agarose in 
3D spheroid formation (30–32). Interestingly, our data also showed 
an increase in cell viability when agarose was added, similarly to that 
observed by Friedrich et al. who noted that spheroid formation and 
growth were superior when wells were coated in agarose (31). It was 
also clear that the integrity and structure of the spheroids were not 
compromised. Therefore, it was determined for this reason that we 
would use the modified hanging drop setup going forward. Agarose 
not only inhibits cell adhesion and is non-toxic but also offers a 
cost-effective alternative to ultra-low adhesion plates.
It is evident from our data that using the CBMN form of the 
MN assay to measure genotoxicity following longer-term expos-
ures (over 24 h) underestimates the true level of genotoxicity. A sig-
nificant difference between the two methods was observed and 
there is a clear trend of a higher MN frequency in mononucleated 
cells. When compared to the untreated control, there was a signifi-
cant increase in MN frequency in mononucleated cells at all ZnO 
ENM concentrations. In contrast, a significant increase in MN fre-
quency in BN cells was only observed at the lower concentration 
Fig. 6. Optimisation of the in vitro micronucleus assay for longer-term ENM genotoxicity assessment. 3D HepG2 spheroids were exposed to increasing 
concentrations of ZnO ENM (0–2.0 µg/ml) and 0.1 µM AFB1 (positive control, +ve) for 5 days and analysed for MN in (A) BN cells (MN/BN %, n = 2) with CBPI 
(n = 2) and (B) mononucleated cells (MN/MN %, n = 3) with RVCC. Statistical significance compared to the untreated control was analysed by Fisher’s exact 
(*P < 0.05). Data shown are expressed as mean ± SD.
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(0.2  µg/ml). It was hypothesised that the damage encountered 
is occurring early on and, therefore, the addition of Cyto B and 
counting of MN in BN cells on the final day is missing the ini-
tial genotoxic insult. Following longer-term exposures, cells will 
have undergone numerous cell divisions and, thus, the addition of 
Cyto B will only capture the cells that have divided in the last cell 
cycle. According to the OECD test guideline 487, measuring cyto-
toxicity by CBPI should only be used following the addition of 
Cyto B (15). Therefore, we suggest that, as an alternative, when 
performing longer-term exposures, cytotoxicity is measured using 
an alternative method, such as RVCC using the TB assay instead. It 
is noted that the OECD test guideline 487 suggests relative popu-
lation doubling (RPD) or relative increase in cell count (RICC) as 
alternative methods when Cyto B is not used to ensure that the 
cells have undergone cell division after extended treatment periods. 
However, based on the nature of the experimental setup of this 3D 
spheroid assay, it would be impractical and costly to set up a satel-
lite plate of spheroids for every concentration to perform the RPD. 
The RICC was also considered, however, as the cells are replicating 
and dividing in the hanging drop during the spheroid formation 
phase, that is, the first 4 days post-seeding and prior to exposure, 
this would also underestimate cytotoxicity. Consequently, due to 
the complex structure of the 3D liver models, the RVCC was calcu-
lated using the TB assay. This method was previously described by 
Roy et al. as a measure of cytotoxicity in the 3D RSMN assay (33). 
The authors measure cytotoxicity using both the CBPI and RVCC, 
identifying that the RVCC was the more sensitive measure of cell 
viability for treatment with N-ethyl-N-nitrosourea and 2-ethyl-1,3-
hexanediol in their 3D skin model. Our data demonstrates no sig-
nificant difference between the RVCC and CBPI and, therefore, is 
put forward as a feasible method for measuring cytotoxicity when 
assessing longer-term genotoxicity using the MN assay in 3D liver 
spheroid models.
In recent decades, there has been a rapid development and im-
plementation of a variety of ENMs used in fields such as food 
and agricultural industry, medical devices and drug delivery. The 
investigation of the potential genotoxicity of these materials over 
acute and longer-term exposure scenarios is a vital component of 
their safety assessment. The in vitro MN assay is deemed the gold 
standard when assessing chromosomal damage induction (specific-
ally clastogenicity and/or aneugenicity); however, this method was 
originally established for use with chemicals and 2D culture sys-
tems. There are many limitations of 2D systems for genotoxicity 
assessment, which have previously been extensively reviewed (34). 
In addition, the regulated genotoxicity in vitro testing methods 
(i.e. for pharmaceuticals) demonstrate ‘low specificity’ and 
‘misleading false positives’ which, at present, results in the re-
quirement for additional animal tests (1,35). It is vital that there 
is continued development of novel advanced in vitro test systems 
and robust protocols, such as 3D in vitro models, that can be used 
as reliable alternatives to animal testing. More importantly, the 
European directive (Directive 2010/63/EU) driving the ‘3Rs’ to re-
duce, replace and refine in vivo animal-based experiments aims to 
advance in vitro-based systems as alternative methods to provide 
predictive and reliable results for hazard assessment (36). With 
advancements in 3D in vitro systems and continuous development 
of novel ENMs, it is essential that we also adapt our current meth-
odologies to evolve with the field. Investigative studies into the 
use of the MN assay for short-term ENM exposures using the 
CBMN assay have identified that Cyto B can halt cellular uptake 
of the novel materials (13,18). Therefore, it was established that 
Cyto B should only be added to the cells post-ENM exposure and 
not as a co-exposure with the ENM, a method that is commonly 
performed with chemical compounds. Recently, Wills et al. have 
successfully adapted the RSMN version of the MN assay for the 
genotoxic assessment of silica nanoparticles in both 2D and 3D in 
vitro models following 24-h exposures (17). Having modified the 
3D liver spheroid system and accompanying MN assay to support 
a longer-term ENM exposure regime, this study demonstrates a 
dose-dependent increase in the frequency of MN following 5 days 
of exposure to ZnO ENM. This would not have been observed 
had methodology alterations not been made. Careful consider-
ation must be taken when using the ‘cytokinesis-block’ version of 
this assay for longer-term exposure regimes, as any DNA damage 
induced within the first few cell cycles is distributed across the 
mononucleated cell population as opposed to being retained and 
scored within the BN cells. This study demonstrates the potential 
to score false negatives, as the DNA damage accumulated over the 
period of chronic exposure can be masked when using the CBMN 
version of the MN assay.
In conclusion, this study has developed a physiologically relevant, 
advanced 3D HepG2 hepatocyte model that demonstrates increased 
efficacy for genotoxicity over 2D monoculture. It also maintains sta-
bility and liver functionality over extended culture periods. Herein, 
the present study has demonstrated the suitability of this model for 
assessing genotoxicity of direct and indirect acting mutagens using 
the regulatory approved in vitro MN assay. Additionally, taking into 
consideration the necessary adaptations, our study demonstrates 
that this model can also be used for the genotoxic assessment of 
ENMs using the MN assay.
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